Literature DB >> 12119608

The genetic basis of variability in drug responses.

Dan M Roden1, Alfred L George.   

Abstract

It is almost axiomatic that patients vary widely in their beneficial responses to drug therapy, and serious and apparently unpredictable adverse drug reactions continue to be a major public health problem. Here, we discuss the concept that genetic variants might determine much of this variability in drug response, and propose an algorithm to enable further evaluation of the benefits and pitfalls of this enticing possibility.

Entities:  

Mesh:

Year:  2002        PMID: 12119608     DOI: 10.1038/nrd705

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  59 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

Review 2.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

3.  Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment.

Authors:  Ina Giegling; Antonio Drago; Martin Schäfer; Annette M Hartmann; Thomas Sander; Mohammad Reza Toliat; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Dan Rujescu; Alessandro Serretti
Journal:  Psychopharmacology (Berl)       Date:  2010-11-16       Impact factor: 4.530

Review 4.  Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.

Authors:  Wolfgang Maier; Astrid Zobel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 5.  The genetics of congestive heart failure.

Authors:  Calum A MacRae
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

6.  Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle.

Authors:  Stephen M Ratchford; Kaleen M Lavin; Ryan K Perkins; Bozena Jemiolo; Scott W Trappe; Todd A Trappe
Journal:  J Appl Physiol (1985)       Date:  2017-07-13

Review 7.  Incorporating Pharmacogenomics into Health Information Technology, Electronic Health Record and Decision Support System: An Overview.

Authors:  Abdullah Alanazi
Journal:  J Med Syst       Date:  2016-12-17       Impact factor: 4.460

8.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

9.  Inconsistency in large pharmacogenomic studies.

Authors:  Benjamin Haibe-Kains; Nehme El-Hachem; Nicolai Juul Birkbak; Andrew C Jin; Andrew H Beck; Hugo J W L Aerts; John Quackenbush
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

10.  Minimally perturbing a gene regulatory network to avoid a disease phenotype: the glioma network as a test case.

Authors:  Guy Karlebach; Ron Shamir
Journal:  BMC Syst Biol       Date:  2010-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.